Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 25;13(1):2902.
doi: 10.1038/s41467-022-30601-3.

Molecular mechanism of the wake-promoting agent TAK-925

Affiliations

Molecular mechanism of the wake-promoting agent TAK-925

Jie Yin et al. Nat Commun. .

Abstract

The OX2 orexin receptor (OX2R) is a highly expressed G protein-coupled receptor (GPCR) in the brain that regulates wakefulness and circadian rhythms in humans. Antagonism of OX2R is a proven therapeutic strategy for insomnia drugs, and agonism of OX2R is a potentially powerful approach for narcolepsy type 1, which is characterized by the death of orexinergic neurons. Until recently, agonism of OX2R had been considered 'undruggable.' We harness cryo-electron microscopy of OX2R-G protein complexes to determine how the first clinically tested OX2R agonist TAK-925 can activate OX2R in a highly selective manner. Two structures of TAK-925-bound OX2R with either a Gq mimetic or Gi reveal that TAK-925 binds at the same site occupied by antagonists, yet interacts with the transmembrane helices to trigger activating microswitches. Our structural and mutagenesis data show that TAK-925's selectivity is mediated by subtle differences between OX1 and OX2 receptor subtypes at the orthosteric pocket. Finally, differences in the polarity of interactions at the G protein binding interfaces help to rationalize OX2R's coupling selectivity for Gq signaling. The mechanisms of TAK-925's binding, activation, and selectivity presented herein will aid in understanding the efficacy of small molecule OX2R agonists for narcolepsy and other circadian disorders.

PubMed Disclaimer

Conflict of interest statement

J.Y., K.C., R.R., P.L., X.B., J.K.D.B., and D.M.R. declare no competing interests. Y.K., A.P.M., M.S., E.K., A.O., T.K., Y.M., Y.S. and M.F. are current or former employees of Takeda Pharmaceutical Company Limited.

Figures

Fig. 1
Fig. 1. Overall structures of the OX2R-G protein complexes.
a Cryo-EM reconstruction of the complex OX2R-mGsqiN. Receptor density is in purple, TAK-925 is yellow, GαsqiN is orange, Gβ1 is green, Gγ2 is pink. The cryo-EM density from Relion was displayed in Chimera as colored surfaces (contour level 0.033, 5 sigma), where different colored zones corresponded to the different polypeptides. b Model of complex as a cartoon, with the TAK-925 agonist as spheres with yellow carbons, blue nitrogens and red oxygens. c Cryo-EM density surrounding the ligand TAK-925 in the complex structure OX2R-mGsqiN, with the TAK-925 agonist as sticks with colored by heteroatom (yellow carbons, blue nitrogens and red oxygens). Cryo-EM density was displayed in Pymol (4.2 sigma) within 2 Å around TAK-925. d Cryo-EM reconstruction of the complex OX2R-Gi1. Receptor density is in purple, TAK-925 is yellow, Gαi1 is blue, Gβ1 is green, Gγ2 is pink. The cryo-EM density from cryoSPARC was displayed in Chimera as colored surfaces (contour level 0.5, 5 sigma), where different colored zones corresponded to the different polypeptides. e Model of complex as a cartoon, with the TAK-925 agonist as spheres with yellow carbons, blue nitrogens and red oxygens. f Cryo-EM density surrounding the ligand TAK-925 in the complex structure OX2R-Gi1, with the TAK-925 agonist as sticks with colored by heteroatom (yellow carbons, blue nitrogens and red oxygens). Cryo-EM density was displayed in Pymol (5 sigma) within 2 Å around TAK-925.
Fig. 2
Fig. 2. Binding of TAK-925 to OX2R.
a Overlay of contact residues (sticks with purple carbons for mGsqiN-coupled OX2R and sticks with blue carbons for Gi1-coupled OX2R) within 4 Å of TAK-925 (yellow carbons) when superimposing OX2R- mGsqiN and OX2R-Gi1. The OX2R backbone (silver) is from OX2R-mGsqiN. The hydrogen bond from Gln1343.32 to TAK-925’s sulfonamide is not shown because this residue is behind the ligand from this viewpoint (same as in Fig. 2c). b Overlay of TAK-925 (sticks with yellow carbons), Compound 1 (sticks with orange carbons) and suvorexant (sticks with cyan carbons) when superimposing the OX2R polypeptides from the OX2R-mGsqiN complex (this work), the OX2R-mini-Gsqi complex (PDB 7L1V) and the antagonist-bound inactive conformation (PDB 4S0V). c Overlay of contact residues within 4 Å of TAK-925 when superimposing OX2R-mGsqiN (this work, magenta), OX2R-mini-Gsqi/Compound 1 (PDB 7L1V, orange) and the suvorexant-bound inactive conformation of OX2R (PDB 4S0V, cyan). TAK-925 is shown as transparent spheres. d Stimulation of Gq by OX2R wild type (WT) and mutants when bound to TAK-925 (top) and orexin B (bottom). Each data point represents an average from n ≥ 3 independent experiments (each performed in duplicate), where n is shown in Supplementary Table 2. Error bars are ±SD. Data were normalized to the WT Emax and fitted to the three-parameter model ‘log(agonist) vs response’ in GraphPad Prism 9. Source data are provided as a Source Data file.
Fig. 3
Fig. 3. Structural basis for high selectivity of TAK-925 for OX2R.
a Overlay of contact residues (sticks with purple carbons for mGsqiN-coupled OX2R and sticks with wheat carbons for inactive OX1R) within 4 Å of TAK-925 (transparent spheres with yellow carbons) when superimposing OX2R-Gq and the antagonist-bound inactive conformation of OX1R (PDB 4ZJ8). Divergent residues are circled by red dotted lines. b Stimulation of Gq by OX1R wild type (WT) and subtype-swap single and double mutants when bound to TAK-925. Each data point represents an average from n = 3 independent experiments (each performed in duplicate). Error bars are ±SD. OX1R data were normalized to S103T/A127T Emax. Data were fitted to the three-parameter model ‘log(agonist) vs response’ in GraphPad Prism 9. Source data are provided as a Source Data file. c Stimulation of Gq by OX2R wild type (WT) and subtype-swap single and double mutants. Each data point represents an average from n ≥ 3 independent experiments (each performed in duplicate), where n is shown in Supplementary Table 2. Error bars are ±SD. OX2R data were normalized to OX2R WT Emax. Data were fitted to the three-parameter model ‘log(agonist) vs response’ in GraphPad Prism 9. Source data are provided as a Source Data file.
Fig. 4
Fig. 4. Propagated changes in OX2R activation.
a Conformational changes of the side chains of key residues at the orthosteric site when bound to agonist, comparing the active conformation (purple sticks, transparent gray cartoon) and the inactive conformation (cyan sticks and transparent cyan cartoon). TAK-925 is shown as yellow sticks and suvorexant is in cyan sticks. b Overlay of PIF transmission switch in the active conformation of OX2R (purple sticks and transparent spheres) and the inactive conformation of OX2R (PDB 4S0V, cyan sticks and transparent spheres). c Rewiring of micro switches on the intracellular side of OX2R when bound to agonist, comparing the active conformation (purple sticks, gray cartoon) and the inactive conformation (cyan sticks). TAK-925 is shown as yellow sticks. d Conformational changes of DRY motif when coupled to G protein, comparing the active conformation (gray cartoon and purple stick) and the inactive conformation (cyan sticks). The H5 helices of Gq and Gi are shown as orange and blue cartoon, respectively. Hydrogen bonds are shown as dotted lines.
Fig. 5
Fig. 5. Interfaces of OX2R-G protein complexes and activation of Gi and Gq.
a Interactions within 4 Å between OX2R and mGsqiN (gray cartoon and purple sticks for OX2R and orange cartoon and sticks for H5 helix of Gq α subunit). Hydrogen bonds are dotted lines. b Interactions within 4 Å between OX2R and Gi1 (gray cartoon and purple sticks for OX2R and blue cartoon and sticks for H5 helix of Gi α subunit). Hydrogen bonds are dotted lines. c Gq signaling mediated by OX2R with TAK-925 or orexin B. Each data point represents an average from n ≥ 3 independent experiments (each performed in duplicate), where n is shown in Supplementary Table 2. Error bars are ±SD. Data were normalized to the orexin B Emax and fitted to the three-parameter model ‘log(agonist) vs response’ in GraphPad Prism 9. Source data are provided as a Source Data file. d Gi signaling mediated by OX2R with TAK-925 or orexin B. Each data point represents an average from 3 independent experiments (each performed in duplicate). Error bars are ±SD. Source data are provided as a Source Data file.

Comment in

References

    1. Li J, Hu Z, Lecea Lde. The hypocretins/orexins: integrators of multiple physiological functions. Br. J. Pharmacol. 2014;171:332–350. doi: 10.1111/bph.12415. - DOI - PMC - PubMed
    1. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharm. Sci. 2006;27:368–374. doi: 10.1016/j.tips.2006.05.006. - DOI - PubMed
    1. Marston OJ, et al. Circadian and dark-pulse activation of orexin/hypocretin neurons. Mol. Brain. 2008;1:19–19. doi: 10.1186/1756-6606-1-19. - DOI - PMC - PubMed
    1. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev. Pharm. 2011;51:243–266. doi: 10.1146/annurev-pharmtox-010510-100528. - DOI - PMC - PubMed
    1. Bassetti CLA, et al. Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat. Rev. Neurol. 2019;15:519–539. doi: 10.1038/s41582-019-0226-9. - DOI - PubMed

Publication types

LinkOut - more resources